Psyence Biomedical Ltd. Common Shares (PBM) - Net Assets
Based on the latest financial reports, Psyence Biomedical Ltd. Common Shares (PBM) has net assets worth $11.87 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($12.81 Million) and total liabilities ($943.07K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Psyence Biomedical Ltd. Common Shares to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $11.87 Million |
| % of Total Assets | 92.64% |
| Annual Growth Rate | 8.78% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 2332.52 |
Psyence Biomedical Ltd. Common Shares - Net Assets Trend (2021–2025)
This chart illustrates how Psyence Biomedical Ltd. Common Shares's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Psyence Biomedical Ltd. Common Shares for the complete picture of this company's asset base.
Annual Net Assets for Psyence Biomedical Ltd. Common Shares (2021–2025)
The table below shows the annual net assets of Psyence Biomedical Ltd. Common Shares from 2021 to 2025. For live valuation and market cap data, see PBM company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | $6.72 Million | +161.26% |
| 2024-03-31 | $-10.97 Million | -104.48% |
| 2023-03-31 | $244.66 Million | +2.01% |
| 2022-03-31 | $239.84 Million | +4895.92% |
| 2021-03-31 | $4.80 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Psyence Biomedical Ltd. Common Shares's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5644720400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $61.75 Million | 918.66% |
| Other Comprehensive Income | $351.20K | 5.22% |
| Other Components | $1.07 Million | 15.85% |
| Total Equity | $6.72 Million | 100.00% |
Psyence Biomedical Ltd. Common Shares Competitors by Market Cap
The table below lists competitors of Psyence Biomedical Ltd. Common Shares ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Capital Drilling Ltd
LSE:CAPD
|
$3.17 Million |
|
KEY Petroleum Ltd
AU:KEY
|
$3.17 Million |
|
Softimat S.A.
BR:SOFT
|
$3.17 Million |
|
Ecobuilt Holdings Bhd
KLSE:0059
|
$3.17 Million |
|
Mexican Gold Corp
V:MEX
|
$3.16 Million |
|
Birddog Technology Ltd
AU:BDT
|
$3.16 Million |
|
Ordissimo
PA:ALORD
|
$3.16 Million |
|
Tree House Education & Accessories Limited
NSE:TREEHOUSE
|
$3.15 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Psyence Biomedical Ltd. Common Shares's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -10,972,540 to 6,722,004, a change of 17,694,544.
- Net income of 1,011,790 contributed positively to equity growth.
- New share issuances of 1,742,051 increased equity.
- Other comprehensive income decreased equity by 9,859.
- Other factors increased equity by 14,950,562.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $1.01 Million | +15.05% |
| Share Issuances | $1.74 Million | +25.92% |
| Other Comprehensive Income | $-9.86K | -0.15% |
| Other Changes | $14.95 Million | +222.41% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Psyence Biomedical Ltd. Common Shares's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.35x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 10.88x to 0.35x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-03-31 | $0.38 | $4.10 | x |
| 2022-03-31 | $7.24 | $4.10 | x |
| 2023-03-31 | $7.49 | $4.10 | x |
| 2024-03-31 | $-1.68 | $4.10 | x |
| 2025-03-31 | $11.83 | $4.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Psyence Biomedical Ltd. Common Shares utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 15.05%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.09x
- Recent ROE (15.05%) is above the historical average (5.45%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 3.48% | 0.00% | 0.00x | 1.08x | $-15.43 Million |
| 2023 | 3.28% | 0.00% | 0.00x | 1.06x | $-16.45 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-50.06 Million |
| 2025 | 15.05% | 0.00% | 0.00x | 1.09x | $339.59K |
Industry Comparison
This section compares Psyence Biomedical Ltd. Common Shares's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $211,624,003
- Average return on equity (ROE) among peers: -53.56%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Psyence Biomedical Ltd. Common Shares (PBM) | $11.87 Million | 3.48% | 0.08x | $3.16 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $98.85 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.59 Billion |
| Abeona Therapeutics Inc (ABEO) | $67.72 Million | -21.45% | 0.18x | $309.44 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $181.29 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $795.12 Million |
| Arbutus Biopharma Corp (ABUS) | $30.03 Million | -30.65% | 0.08x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $2.46 Million | -172.46% | 1.68x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $18.59 Million | -164.77% | 1.78x | $9.67 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $479.08 Million | -51.18% | 0.13x | $3.61 Billion |
About Psyence Biomedical Ltd. Common Shares
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for … Read more